Table: Sumitomo Pharma -Q1 group results (IFRS)

Sumitomo Pharma

31/07/2026 07:32

   Jul 31 (Reuters)- 
              Sumitomo Pharma Co., Ltd. 
              CONSOLIDATED FINANCIAL HIGHLIGHTS 
     (in billions of yen unless specified) 
                 3 months ended      3 months ended       Year to 
                Jun 30, 2026        Jun 30, 2025     Mar 31, 2027 
                   LATEST             YEAR-AGO          COMPANY   
                   RESULTS             RESULT          FORECAST   
  Sales            129.50              108.00           540.00    
                 (+19.9 pct)         (+19.1 pct)      (+19.1 pct) 
  Operating         18.19               20.40            90.00    
                 (-10.8 pct)                          (-16.2 pct) 
  Pretax
  Net               17.00               11.21            77.00    
                 (+51.7 pct)         (-29.7 pct)      (-27.9 pct) 
  EPS Basic       39.02 yen           28.21 yen       172.89 yen  
  Ann Div                                NIL                      
  -Q2 Div                                NIL                      
  -Q4 Div                                NIL                      
 
  NOTE - Sumitomo Pharma Co., Ltd.. 
  (Figures are reported based on international accounting rules (IFRS).) 
  If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half 
  dividend and Q4 to the second-half dividend announced before a new corporate law in 
  2006 allowed companies to pay and report dividends on a quarterly basis.
  *Net - represents Net profit attributable to owners of the parent company. 
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4506.T